Quick answer
Why do peptides matter in research? Peptides are short chains of amino acids that the body already uses as hormones and signals, so they give researchers a direct way to study receptors and pathways. Reviews describe them as highly selective and efficacious, and the field has a long track record: one 2021 perspective counts more than 80 peptide drugs on the market since insulin was introduced almost a century ago. Their weaknesses are equally well documented, mainly poor pharmacokinetic properties, which is why so much research effort goes into chemical modification. For laboratories, peptides are useful reference tools because their sequence can be written down, synthesized and checked analytically. The products on this site are supplied for laboratory research use only; not for human consumption.
It is easy to say that peptides are "important" without saying why. The real reasons are specific. Peptides are the native language of many signaling systems, they bind receptors with high selectivity, they can be made by chemical synthesis with exact sequences, and they can be redesigned in controlled steps. They also have characteristic weaknesses that shape how they are handled in a laboratory. This article lays out each point with the literature behind it. It is a general scientific overview, not guidance on any use outside research. For the definition of the category, start with what are research peptides.
Peptides are the body's own signals
A peptide is a short chain of amino acids. Many hormones and neuromodulators are peptides, which means that studying them is studying physiology directly. A good example is the discovery of the incretin peptide GLP-1. Mojsov and colleagues reported in 1987 that a glucagon-like peptide, co-encoded with glucagon in the glucagon gene, was a potent stimulator of insulin secretion. They showed that the proglucagon precursor contains glucagon and additional glucagon-like peptides that are liberated in both the pancreas and the intestine, and that in the isolated perfused rat pancreas, GLP-I(7-37) stimulated insulin secretion at concentrations as low as 5 × 10⁻¹¹ M while GLP-I(1-37) had no effect even at 5 × 10⁻⁷ M. A single gene yielding several related signals, with the activity residing in a specific truncated form, is a typical peptide-biology story, and it illustrates why exact sequence matters. The later evolution of that peptide into engineered analogs is traced in what is Sema and in the V8 article on the semaglutide research literature.
Another example is the receptor for the growth hormone secretagogues. Howard and colleagues cloned a G protein-coupled receptor of the pituitary and hypothalamus that was the target of synthetic secretagogues and argued that these molecules mimic an undiscovered hormone. Kojima and colleagues then isolated that hormone, ghrelin, an acylated peptide from stomach. Here synthetic peptides led researchers to a receptor, and the receptor led them to a natural peptide. The pattern appears throughout endocrinology, and it is one reason tool peptides stay relevant in basic science: they are probes that can be matched to natural counterparts. See what is hexarelin for one such tool.
Selectivity and a long track record
Fosgerau and Hoffmann describe peptides as being recognized for high selectivity and efficacy and, at the same time, as relatively safe and well tolerated in the pharmaceutical context, noting approximately 140 peptide candidates being evaluated in clinical trials at the time of writing. Lau and Dunn's overview states that peptides have played a notable role in medical practice since the advent of insulin in the 1920s, that over 60 peptide drugs were approved in the United States and other major markets, and that their dataset included over 150 peptides in active development. Muttenthaler and colleagues counted more than 80 peptide drugs on the market for a wide range of diseases. Counts differ because the reviews were written in different years and use different inclusion rules, so they are best read as order-of-magnitude statements about a mature field.
These numbers refer to pharmaceutical development, which is outside the scope of laboratory research materials. They are cited here only to explain why peptide chemistry is such a well-developed discipline and why analytical standards, such as purity by HPLC and identity confirmation, are so well established. The methods developed for that field are the ones research laboratories borrow to characterize their own reagents.
| Review | Reported point | Relevance for research use |
|---|---|---|
| Fosgerau and Hoffmann (2015) | Peptides are highly selective and efficacious; about 140 in clinical evaluation; new design routes include multifunctional, cell-penetrating peptides and conjugates | Selectivity is why peptides serve as receptor probes |
| Lau and Dunn (2018) | Over 60 approved peptide drugs; over 150 in active development; diversification beyond endogenous human peptides | Shows the breadth of sequence sources and chemistries |
| Muttenthaler et al. (2021) | More than 80 peptide drugs on the market; trends from human hormones to venom-derived and display-library peptides | Traces the design strategies behind modern analogs |
| Henninot et al. (2018) | Revival of interest; focus on overcoming poor pharmacokinetic properties | Explains why modification chemistry dominates the field |
| Vlieghe et al. (2010) | Synthetic strategies for limiting metabolism produced many marketed peptide-based drugs | Links synthesis methods to stability |
Nature as a source: from hormones to venom
Peptides do not only come from human physiology. Eng and colleagues isolated exendin-4, a 39-amino-acid peptide, from the venom of Heloderma suspectum, and Göke and colleagues later showed that it is an agonist at the GLP-1 receptor, with a truncated form, exendin-(9-39)-amide, acting as a specific antagonist. Muttenthaler and colleagues explicitly list peptide drugs derived from nature, along with integrated venomics and peptide-display libraries, among the key trends. For researchers the practical meaning is that a peptide with a different sequence can address the same receptor, and that agonist and antagonist pairs derived from one scaffold are available as controls.
Engineering peptides: fixing weaknesses one change at a time
The same reviews that praise selectivity stress that native peptides have inherent weaknesses, especially poor pharmacokinetic behavior, and that the history of the field is largely a history of fixes. Henninot and colleagues emphasize research efforts to overcome these weaknesses. Vlieghe and colleagues report that new synthetic strategies for limiting metabolism produced a large number of marketed peptide-based drugs. The semaglutide discovery paper by Lau and colleagues is a worked example: starting from the acylated analog liraglutide, the team aimed to increase albumin affinity and secure full stability against metabolic degradation, ending with a molecule with two amino acid substitutions (Aib8, Arg34) and a derivatized lysine at position 26. The plasma half-life they reported in mini-pigs was 46.1 hours after intravenous administration. In a different design direction, the IGF-1 analog LR3 changes only a few features of the native sequence and sharply reduces binding to carrier proteins; see the IGF-1 LR3 overview.
| Typical weakness of a native peptide | Engineering response described in the literature | Example in this library |
|---|---|---|
| Metabolic instability | Substitutions at vulnerable positions, D-amino acids, other synthetic strategies | Hexarelin carries two D-amino acids |
| Short exposure in circulation | Reversible albumin binding through a fatty acid and linker | Semaglutide, as described by Lau et al. and Knudsen and Lau |
| Sequestration by carrier proteins | Sequence changes that reduce binding-protein affinity | IGF-1 LR3 |
| Limited delivery options | Alternative routes and formulation strategies discussed in the reviews | Outside the scope of laboratory reagents |
Short sequences, specific functions
Not every useful peptide is a drug candidate. Sometimes a short sequence is valuable because it carries one function of a larger protein. Sosne and colleagues' review describes how particular activities of thymosin beta-4 map onto short sequences: an amino-terminal tetrapeptide linked to blocking inflammation and reducing fibrosis, and a short sequence containing the central actin-binding domain, residues 17–23 plus one additional amino acid, linked to angiogenesis, wound healing and cell migration. Fragments like these let a laboratory ask which part of a large protein is responsible for an observed behavior. The relationship between the full protein and the fragment sold as TB-500 is unpacked in TB-500 versus thymosin beta-4.
Why laboratories like peptides as reagents
From a bench perspective, peptides offer practical advantages that other classes of reagents do not always match.
| Property | Why it helps in research |
|---|---|
| Defined sequence | The molecule can be written down and verified; two batches should match on identity |
| Chemical synthesis | Non-natural residues, labels and modifications can be introduced by design |
| Receptor specificity | A well-characterized peptide can act as a reference agonist or antagonist |
| Analytical tractability | HPLC and mass spectrometry give purity and identity evidence per batch |
| Natural counterpart | Tool peptides can be compared with the endogenous molecule |
The same properties make documentation central. A certificate of analysis should show compound identity, measured purity, lot number and test date; the guide how to read a COA walks through each field, HPLC versus mass spectrometry explains why two methods are paired, and certificates, where published, are in the COA library.
What makes peptides hard to work with
The reviews' emphasis on weaknesses has a laboratory counterpart. Peptides are sensitive to storage conditions, often adsorb to surfaces, and can degrade by oxidation or other routes. Goebel-Stengel and colleagues published a paper specifically on the importance of choosing optimal plasticware and glassware for studies involving peptides, which reflects how routinely surface losses affect results. Practical consequences include low-binding labware, light protection for sensitive sequences, aliquoting rather than repeated freeze-thaw cycles, and storing lyophilized material cold and dry. Stock arithmetic is simple: concentration equals mass divided by volume, and the reconstitution calculator removes arithmetic errors. Details are in how to reconstitute a lyophilized peptide and storing research peptides.
What this article does not claim
Pointing to the importance of peptides in pharmaceutical science is not a statement about any product on this site. The compounds in the research catalog are laboratory reagents, supplied for research use only, and the reviews cited here concern peptide drug development, which is a separate, regulated field. Nothing in this article describes a benefit, use or outcome in people.
Frequently asked questions
What is a peptide?
A short chain of amino acids. Many hormones and signaling molecules are peptides, which is why they are central to endocrinology and receptor biology.
Why are peptides described as selective?
Reviews describe peptides as highly selective and efficacious in their interactions with targets. In the lab this makes a well-characterized peptide a useful probe for a single receptor or pathway.
How established is the field?
Reviews date its practical history to insulin in the 1920s and report dozens of marketed peptide drugs, counting more than 60 in one overview and more than 80 in another. The numbers vary by year and inclusion rules.
What is the main weakness of native peptides?
Poor pharmacokinetic properties, according to reviews of peptide drug discovery. That is why modification chemistry such as stabilizing substitutions and albumin-binding side chains is so prominent.
Can a peptide come from venom?
Yes. Exendin-4 was isolated from the venom of Heloderma suspectum and was later shown to be a GLP-1 receptor agonist.
Why do researchers use short fragments of larger proteins?
To ask which region of a protein is responsible for a particular activity. For thymosin beta-4, reviews map several activities to short sequences, including a central actin-binding region.
Why does a certificate of analysis matter more for peptides?
Because purity and identity are batch-specific, and two peptides with similar names can differ in sequence or size. A certificate should state identity, measured purity, lot and test date.
Why does labware choice matter for peptide experiments?
Peptides can adsorb to plastic and glass, so dilute solutions may lose material. Low-binding labware and minimal transfers reduce the loss.
Are the pharmaceutical figures in this article about V8 products?
No. They come from literature reviews of peptide drug development. V8 products are laboratory reagents for research use only.
Where should a new reader start?
With the definition page on research peptides, then a compound overview such as hexarelin, IGF-1 LR3, semaglutide or TB-500, each of which lists model systems and citations.
All material discussed is supplied for laboratory research use only; not for human consumption.
Related reading: Why Sexual Desire Declines With Age: What Studies Report, Workout Recovery: What the Evidence Shows by Strategy, Spotting Unreliable Peptide Sellers: A Test Sheet.
References
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128. doi:10.1016/j.drudis.2014.10.003
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. doi:10.1038/s41573-020-00135-8
- Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707. doi:10.1016/j.bmc.2017.06.052
- Henninot A, Collins JC, Nuss JM. The current state of peptide drug discovery: back to the future? J Med Chem. 2018;61(4):1382-1414. doi:10.1021/acs.jmedchem.7b00318
- Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15(1-2):40-56. doi:10.1016/j.drudis.2009.10.009
- Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79(2):616-619. doi:10.1172/JCI112855
- Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230
- Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. 1992;267(11):7402-7405. PMID: 1313797
- Göke R, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650-19655. PMID: 8396143
- Lau J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. doi:10.1096/fj.09-142307
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
